This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Thoratec's CEO Discusses Q3 2011 Results - Earnings Call Transcript

We caution you that these statements are only predictions and that actual results may differ materially. We also alert you to the risks contained in the documents we file with the Securities and Exchange Commission, such as our annual and quarterly reports on Forms 10-K and 10-Q. We do not undertake any obligation to update or correct any forward-looking statements. Gary?

Gary Burbach

Thank you, Taylor, and good afternoon, everyone. Thoratec’s third quarter was highlighted by continued double-digit growth year-over-year in both pump units and revenues, strong new center activity, gross margin performance above our expectations and continued execution on our product and market development strategies. We experienced a sequential decline from our strong second quarter revenue performance and based on a few factors that we will described later, we are reducing our full-year revenue outlook by 1% to 2%. That said, we believe that the VAD market remains healthy and on track for sustained longer-term growth.

Additionally, based on our strong profitability results year-to-date, we are raising our 2011 guidance for gross margin and earnings per share. With respect to our financial results for the quarter, Thoratec generated revenues of $102.6 million, a 13% increase over revenues of $91.0 million in the third quarter of 2010. This increase was driven by a strong growth in pump revenues of 15%, with non-pump revenues continuing to expand at a slower pace due largely to the comparison against last year’s HeartMate external peripherals upgrade cycle.

Revenues moderated on a sequential basis reflecting the seasonality we typically see in the third quarter as well as the particularly strong performance in the second quarter of this year. In terms of geographic breakdown for the third quarter, we recorded revenues of $83.9 million in the United States versus $76.4 million in the prior year, an increase 10%. While international revenues were $18.7 million versus $14.6 million a year ago, representing an increase of 28% or 8% excluding both the positive $1.5 million impact of FX versus the third quarter of 2010 as well as the incremental international revenues associated with the Levitronix Medical acquisition.

2 of 4

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $95.36 1.80%
FB $117.65 -0.78%
GOOG $696.01 -0.32%
TSLA $234.46 -3.00%
YHOO $36.20 -0.90%


Chart of I:DJI
DOW 17,782.48 -108.68 -0.61%
S&P 500 2,063.17 -18.26 -0.88%
NASDAQ 4,771.4650 -46.1290 -0.96%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs